Effect of Gefitinib combined with compound matrine injection on patients with advanced lung cancer after chemotherapy

Abstract

Objective To investigate the effect of toxicity reduting and efficacy enhancing of Gefitinib combined with compound matrine injection on patients with advanced lung cancer after chemotherapy. Methods Eighty-eight patients with advanced lung cancer in Peking University Shenzhen Hospital from December 2016 to May 2018 were randomly divided into observation group and control group, with 44 cases in each group. Both groups were treated with routine chemotherapy regimens. The patients in control group were given Gefitinib, 1 tablet for 1 day. Based on the treatment in control group, the patents in treatment group were treated with compound matrine injection, 12 ml/time, once a day. Both groups were treated for 6 weeks. The recent efficacy, myelosuppression change, and life quality scores were compared between two groups. Results The recent total efficacy rate of observation group was 81.82%, which was higher than that of control group(59.09%, P<0.05). The number of neutrophils, hemoglobin, platelets, and white blood cells was obviously higher than those of control group after treatment(P<0.01). The life quality scores of observation group were obviously higher than those of control group(P<0.01). Conclusions Gefitinib combined with compound matrine injection can improve the recent effects on advanced lung cancer after chemotherapy, and reduce the toxicity of hematology, improve the life quality. Key words: Gefitinib; Compound matrine injection; Lung cancer; Toxicity reduting and efficacy enhancing